- Home
- RVT vs RDY Comparison
RVT vs RDY Comparison
Compare RVT & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- RDY
- Stock Information
- Founded
- RVT 1986
- RDY 1984
- Country
- RVT United States
- RDY India
- Employees
- RVT N/A
- RDY N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- RVT Finance
- RDY Health Care
- Exchange
- RVT Nasdaq
- RDY Nasdaq
- Market Cap
- RVT 1.9B
- RDY 2.1B
- IPO Year
- RVT N/A
- RDY N/A
- Fundamental
- Price
- RVT $13.61
- RDY $13.68
- Analyst Decision
- RVT
- RDY Buy
- Analyst Count
- RVT 0
- RDY 1
- Target Price
- RVT N/A
- RDY $17.00
- AVG Volume (30 Days)
- RVT 243.4K
- RDY 2.9M
- Earning Date
- RVT 01-01-0001
- RDY 05-06-2025
- Dividend Yield
- RVT 7.32%
- RDY 3.50%
- EPS Growth
- RVT N/A
- RDY 2.68
- EPS
- RVT 2.95
- RDY 0.75
- Revenue
- RVT N/A
- RDY $3,637,607,642.00
- Revenue This Year
- RVT N/A
- RDY $17.23
- Revenue Next Year
- RVT N/A
- RDY $9.19
- P/E Ratio
- RVT $4.98
- RDY $18.46
- Revenue Growth
- RVT N/A
- RDY 14.74
- 52 Week Low
- RVT $11.85
- RDY $12.26
- 52 Week High
- RVT $14.93
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- RVT 47.39
- RDY 58.00
- Support Level
- RVT $13.00
- RDY $13.27
- Resistance Level
- RVT $13.50
- RDY $13.04
- Average True Range (ATR)
- RVT 0.55
- RDY 0.36
- MACD
- RVT 0.08
- RDY 0.11
- Stochastic Oscillator
- RVT 73.76
- RDY 84.52
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.